Role of nebulized epinephrine in moderate bronchiolitis: a quasi-randomized trial

Ir J Med Sci. 2021 Feb;190(1):239-242. doi: 10.1007/s11845-020-02293-5. Epub 2020 Jul 10.

Abstract

Background/aims: Bronchiolitis is the most common lower respiratory illness that characteristically affects the children below 2 years of age accounting about 2-3% of patients admitted to hospital each year [1-4]. We compared the effect of racemic epinephrine (RE) and 3% hypertonic saline (HS) nebulization on the length of stay (LOS) in the hospital.

Methods: We looked at the infants with moderate bronchiolitis, from October 2013 to March 2014. Out of eighty cases, 16 in HS and 18 in RE groups were enrolled. At the time of admission, 0.2 ml of RE added to 1.8 ml of distilled water was nebulized to RE group, as compared with 2 ml of 3% HS in nebulized form. RE was re-administered if needed on 6 h in comparison with 3% HS at the frequency of 1 to 4 h.

Results: One infant from RE group and three infants from HS group were excluded due to progression towards severe bronchiolitis. The LOS in RE group ranged between 18 and 160 h (mean 45 h), while in HS group, LOS was 18.50-206 h (mean 74.3 h). The LOS was significantly short in RE group (p value 0.015) which was statistically significant.

Conclusion: Racemic epinephrine nebulization as first-line medication may significantly reduce the length of hospital stay in infants with moderate bronchiolitis in comparison with nebulized HS.

Keywords: Bronchiolitis; Epinephrine; Hypertonic saline; Length of Hospital stay.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Bronchiolitis / drug therapy*
  • Bronchodilator Agents / pharmacology
  • Bronchodilator Agents / therapeutic use*
  • Child, Preschool
  • Epinephrine / pharmacology
  • Epinephrine / therapeutic use*
  • Female
  • Humans
  • Infant
  • Male
  • Nebulizers and Vaporizers / standards*

Substances

  • Bronchodilator Agents
  • Epinephrine